目的:探讨n 125I放射性粒子植入联合间歇性内分泌治疗对前列腺癌的临床疗效。n 方法:选取2016年5月至2017年5月赤峰学院附属医院收治的84例活检病理诊断为Tn 3Nn 0Mn 0的前列腺癌患者作为研究对象，采用随机数字表法分为2组，对照组40例采用间歇性内分泌治疗(IHT)，观察组44例采用n 125I放射性粒子植入联合IHT治疗，观察两组患者初次IHT后前列腺特异抗原(PSA)恢复正常时间、间歇期时间，记录两组治疗期间PSA水平动态变化及预后生存情况。n 结果:观察组初次IHT后PSA恢复正常时间短于对照组，IHT后间歇期时间长于对照组(n P<0.05)；观察组治疗3、6、12、24个月PSA水平均低于对照组(n P<0.05)；观察组2年PSA-无进展生存(PSA-PFS)率为77.27%，高于对照组的45.0%，差异有统计学意义(n P0.05)；观察组患者治疗期间未出现严重并发症。n 结论:125I放射性粒子植入联合IHT治疗前列腺癌，可更快地降低PSA水平，提高2年PSA-PFS率。n “,”Objective:To explore clinical effect of n 125I radioactive seed implantation combined with intermittent hormonal therapy (IHT) on prostate cancer.n Methods:During the period from May 2016 to May 2017, 84 patients pathologically diagnosed with prostate cancer of Tn 3Nn 0Mn 0 by biopsy in Affiliated Hospital of Chifeng College were enrolled as study objects. They were divided into two groups by random number table method. 40 cases in control group were treated with intermittent hormonal therapy, while 44 cases in observation group were treated with n 125I radioactive seed implantation combined with IHT. After the first IHT, time of prostate specific antigen (PSA) returning to normal and intermission time in both groups were observed. The dynamic changes of PSA level and prognosis in both groups during treatment were recorded.n Results:After the first IHT, time of PSA returning to normal in observation group was shorter than that in control group, while intermission time was longer than that in control group (n P<0.05). At 3, 6, 12 and 24 months after treatment, PSA level in observation group was lower than that in control group (n P<0.05). The 2-year PSA-free progression survival (PSA-PFS) rate in observation group was higher than those in control group (77.27% vs 45.0%) (n P0.05). There were no serious complications during treatment in observation group.n Conclusions:125I radioactive seed implantation combined with IHT in treatment of prostate cancer can reduce PSA level more quickly, and increase 2-year PSA-PFS rate.n